Key result
Review highlights the clinical and diagnostic value of highly sensitive cardiac troponins and myeloperoxidase.
Why the study?
Searching for new cardiovascular disease biomarkers and clarifying their clinical and diagnostic value is needed to improve diagnosis, prognosis, and therapy.
This review summarizes the clinical and diagnostic utility of new cardiovascular biomarkers, including highly sensitive cardiac troponins and myeloperoxidase.
Should not yet change biomarker strategies in practice; leaves open prospective validation of hs-cTn and myeloperoxidase.
Laboratory biomarkers of cardiovascular diseases play a crucial role in confirming the diagnosis, establishing the prognosis of patients, and correcting therapy. Therefore, the search for new cardiovascular diseases biomarkers, as well as the study and clarification of their clinical and diagnostic value, is an important task of modern healthcare. This article discusses the clinical and diagnostic value of new cardiovascular diseases biomarkers. The classification of cardiovascular diseases biomarkers is given. In a comparative aspect, new markers specific to myocardial tissue (highly sensitive cardiac troponins) are considered. Some new non-myocardial tissue-specific markers, in particular myeloperoxidase, are also discussed.
No takes yet. Share an insight, caveat, or question.
Aleksey M. Chaulin (2021) conducted a review in Cardiovascular diseases. New cardiovascular biomarkers (highly sensitive cardiac troponins, myeloperoxidase) was evaluated. This literature review discusses the clinical and diagnostic value of new cardiovascular biomarkers, specifically highlighting highly sensitive cardiac troponins and myeloperoxidase.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: